GEORGE S. DREW
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- Marion, OH
- NPI
- 1245298009
- Received
- $1,933,192 in 3,152 records, 2019 to 2025
- As principal investigator
- $75,675 of research payments to others in 89 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 541 | $395,916 |
| 2024 | General payment | 570 | $444,880 |
| 2023 | General payment | 576 | $469,103 |
| 2022 | General payment | 502 | $265,213 |
| 2021 | General payment | 253 | $124,372 |
| 2020 | General payment | 246 | $86,313 |
| 2019 | General payment | 464 | $147,391 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 351 | $1,180,608 |
| Consulting Fee | 125 | $352,515 |
| Travel and Lodging | 576 | $224,500 |
| Food and Beverage | 2,056 | $59,942 |
| Compensation for serving as faculty or as a speaker for a medical education program | 12 | $56,230 |
| Honoraria | 9 | $34,900 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 7 | $23,400 |
| Education | 16 | $1,095 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Incyte Corporation | $815 | Consulting Fee | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-23 | LEO Pharma Inc. | $9 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-12-23 | LEO Pharma Inc. | $9 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-12-18 | LEO Pharma Inc. | $5,430 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-18 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-12-18 | Arcutis Biotherapeutics, Inc. | $750 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-18 | UCB, Inc. | $24 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-17 | UCB, Inc. | $5 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-16 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,840 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-12-16 | SUN PHARMACEUTICAL INDUSTRIES INC. | $602 | Travel and Lodging | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-12-16 | SUN PHARMACEUTICAL INDUSTRIES INC. | $264 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-12-15 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-12 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $113 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-12-09 | LEO Pharma Inc. | $994 | Travel and Lodging | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-09 | LEO Pharma Inc. | $75 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-09 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-09 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-09 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | LEO Pharma Inc. | $834 | Travel and Lodging | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-12-08 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | In-kind items and services | Leqselvi Biological, Dermatology | 2025 | |
| 2025-12-04 | Kowa Pharmaceuticals America, Inc. | $4,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-12-04 | Kowa Pharmaceuticals America, Inc. | $4,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-12-04 | Incyte Corporation | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Kowa Pharmaceuticals America, Inc. | $1,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-12-01 | ABBVIE INC. | $6,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-01 | E.R. Squibb & Sons, L.L.C. | $1,960 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-11-26 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-25 | LEO Pharma Inc. | $12 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-25 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-25 | Arcutis Biotherapeutics, Inc. | $4 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-25 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-24 | LEO Pharma Inc. | $30 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-20 | Incyte Corporation | $708 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-20 | Incyte Corporation | $145 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-20 | Incyte Corporation | $75 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-20 | Incyte Corporation | $55 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-19 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-18 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-18 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-18 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-17 | Ortho Dermatologics, a division of Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-11-17 | Ortho Dermatologics, a division of Bausch Health US, LLC | $22 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-11-17 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-14 | LEO Pharma Inc. | $20 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-14 | LEO Pharma Inc. | $7 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-13 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-12 | Kowa Pharmaceuticals America, Inc. | $89 | Food and Beverage | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-12 | LEO Pharma Inc. | $28 | Food and Beverage | In-kind items and services | SPEVIGO Biological, DERMATOLOGY | 2025 | |
| 2025-11-12 | LEO Pharma Inc. | $11 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-12 | UCB, Inc. | $8 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-11 | Kowa Pharmaceuticals America, Inc. | $961 | Travel and Lodging | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-11 | Kowa Pharmaceuticals America, Inc. | $122 | Food and Beverage | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-11 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-10 | Kowa Pharmaceuticals America, Inc. | $1,654 | Travel and Lodging | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-10 | Kowa Pharmaceuticals America, Inc. | $116 | Food and Beverage | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-10 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-10 | Kowa Pharmaceuticals America, Inc. | $12 | Travel and Lodging | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-06 | ABBVIE INC. | $1,202 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | ABBVIE INC. | $90 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-05 | Incyte Corporation | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | $70 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-29 | ABBVIE INC. | $47 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-23 | LEO Pharma Inc. | $2,263 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-23 | LEO Pharma Inc. | $1,200 | Consulting Fee | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-23 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-22 | MAYNE PHARMA COMMERCIAL LLC | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-22 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-22 | MAYNE PHARMA COMMERCIAL LLC | $2 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-20 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-17 | GENZYME CORPORATION | $12,384 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | GENZYME CORPORATION | $654 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-17 | GENZYME CORPORATION | $75 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | GENZYME CORPORATION | $65 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-16 | Kowa Pharmaceuticals America, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-10-16 | UCB, Inc. | $15 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-10-15 | LEO Pharma Inc. | $28 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-15 | UCB, Inc. | $6 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-10-15 | LEO Pharma Inc. | $2 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-14 | Ortho Dermatologics, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-10-13 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-11 | ABBVIE INC. | $130 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-11 | Regeneron Healthcare Solutions, Inc. | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-09 | Galderma Laboratories, L.P. | $409 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-09 | Arcutis Biotherapeutics, Inc. | $188 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-09 | Galderma Laboratories, L.P. | $125 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-09 | Galderma Laboratories, L.P. | $114 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-09 | Galderma Laboratories, L.P. | $67 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-09 | Galderma Laboratories, L.P. | $30 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-09 | Galderma Laboratories, L.P. | $11 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-08 | ABBVIE INC. | $875 | Consulting Fee | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-07 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-10-07 | LEO Pharma Inc. | $10 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-06 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-10-06 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-10-06 | Arcutis Biotherapeutics, Inc. | $5 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-02 | Ortho Dermatologics, a division of Bausch Health US, LLC | $8,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $750 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-02 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-02 | Biofrontera Inc. | $19 | Food and Beverage | In-kind items and services | AMELUZ Drug, DERMATOLOGY | 2025 | |
| 2025-10-02 | GENZYME CORPORATION | $17 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-02 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-01 | UCB, Inc. | $5 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-30 | UCB, Inc. | $22 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-30 | Galderma Laboratories, L.P. | $9 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPEVIGO Drug, IMMUNOLOGY | 2025 | |
| 2025-09-29 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-27 | Biofrontera Inc. | $47 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-26 | Arcutis Biotherapeutics, Inc. | $6,937 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-26 | Ortho Dermatologics, a division of Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $766 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $682 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $380 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $232 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $90 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $45 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $41 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $15 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $15 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-09-24 | Incyte Corporation | $74 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-24 | UCB, Inc. | $10 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-24 | UCB, Inc. | $6 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-23 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-22 | Arcutis Biotherapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-22 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $29 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $11,938 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $4,298 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-15 | Janssen Biotech, Inc. | $29 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-13 | Regeneron Healthcare Solutions, Inc. | $630 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-13 | Regeneron Healthcare Solutions, Inc. | $33 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-12 | Regeneron Healthcare Solutions, Inc. | $123 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-10 | Medimetriks Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | Neo-Synalar Drug, Dermatology | 2025 | |
| 2025-09-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | $12 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-09-08 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-08 | LEO Pharma Inc. | $10 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-09-04 | ABBVIE INC. | $6,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-04 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-03 | Incyte Corporation | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-09-03 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10 | Food and Beverage | In-kind items and services | Leqselvi Biological, Dermatology | 2025 | |
| 2025-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $32 | Food and Beverage | In-kind items and services | SPEVIGO Drug, IMMUNOLOGY | 2025 | |
| 2025-09-02 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-02 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-29 | Galderma Laboratories, L.P. | $8,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-28 | ABBVIE INC. | $105 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | $14 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-27 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-08-27 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-27 | Janssen Biotech, Inc. | $5 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-26 | UCB, Inc. | $11 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-26 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $22 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-08-25 | Galderma Laboratories, L.P. | $16 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-25 | UCB, Inc. | $5 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-23 | Galderma Laboratories, L.P. | $591 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-23 | Galderma Laboratories, L.P. | $112 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-22 | Incyte Corporation | $126 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-22 | Incyte Corporation | $86 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-21 | UCB, Inc. | $34 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-20 | Arcutis Biotherapeutics, Inc. | $1,500 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | $135 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-20 | Ortho Dermatologics, a division of Bausch Health US, LLC | $22 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-08-20 | LEO Pharma Inc. | $19 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $7 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-19 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-19 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-16 | Regeneron Healthcare Solutions, Inc. | $358 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,840 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | $995 | Travel and Lodging | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | $99 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-14 | UCB, Inc. | $10 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-14 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-13 | ABBVIE INC. | $1,397 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-13 | ABBVIE INC. | $112 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-13 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-13 | Arcutis Biotherapeutics, Inc. | $6 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-13 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-12 | ABBVIE INC. | $6,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-12 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-08-12 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-12 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-11 | Galderma Laboratories, L.P. | $128 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-08 | Ortho Dermatologics, a division of Bausch Health US, LLC | $8,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-08-05 | UCB, Inc. | $2,250 | Consulting Fee | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-01 | Galderma Laboratories, L.P. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-31 | UCB, Inc. | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-31 | Galderma Laboratories, L.P. | $20 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | $12 | Food and Beverage | In-kind items and services | Leqselvi Biological, Dermatology | 2025 | |
| 2025-07-29 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-07-29 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-07-29 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-26 | Janssen Biotech, Inc. | $5,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-26 | Janssen Biotech, Inc. | $1,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-25 | Regeneron Healthcare Solutions, Inc. | $1,671 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-25 | ABBVIE INC. | $67 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-25 | Ortho Dermatologics, a division of Bausch Health US, LLC | $33 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-07-24 | UCB, Inc. | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-24 | Ortho Dermatologics, a division of Bausch Health US, LLC | $756 | Travel and Lodging | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 |
The latest 200 records of 3,152.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $139 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $184 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $163 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $119 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $139 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $142 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $139 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $142 | A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PL | 2024 |
| 2024-01-02 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-01-02 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $741 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $2,530 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $600 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $500 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $1,000 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $5,000 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $1,154 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $1,000 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-11-09 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $1,400 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $805 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $789 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-09-13 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $676 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-05-31 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $928 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-05-31 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $789 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-05-31 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $805 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-05-31 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $789 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2023-05-31 | Dermavant Sciences, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $1,045 | A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of pla | 2023 |
| 2022-10-13 | UCB SA | DERMATOLOGY ASSOCIATES OF MID OHIO | $4,000 | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL AR | 2022 |
| 2022-03-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2022 |
| 2022-01-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $110 | Flare Prevention Phase IIb Trial in GPP | 2022 |
| 2021-02-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-02-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-02-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-02-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-02-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2021 |
| 2021-01-08 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $1,025 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2021 |
| 2021-01-08 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $1,025 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2021 |
| 2021-01-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $3,280 | Flare Prevention Phase IIb Trial in GPP | 2021 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $389 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $389 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $1,025 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $1,025 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $1,025 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $1,025 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $1,025 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $389 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $389 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $389 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-07 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-12-07 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-10-23 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $820 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2020 |
| 2020-10-23 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $820 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2020 |
| 2020-10-09 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $820 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2020 |
| 2020-10-09 | SANOFI US SERVICES INC. | DERMATOLOGY ASSOCIATES OF MID OHIO | $820 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2020 |
| 2020-09-30 | UCB SA | DERMATOLOGY ASSOCIATES OF MID-OHIO | $284 | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL AR | 2020 |
| 2020-09-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID-OHIO | $9,313 | Flare Prevention Phase IIb Trial in GPP | 2020 |
| 2020-09-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-09-18 | UCB SA | DERMATOLOGY ASSOCIATES OF MID-OHIO | $800 | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL AR | 2020 |
| 2020-08-24 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-08-24 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-08-24 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-08-24 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-08-03 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-06-22 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-06-19 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-06-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-06-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-05-20 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-04-27 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-04-16 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-02-24 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-01-02 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2020-01-02 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2020 |
| 2019-10-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-10-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-10-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-10-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-09-03 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-07-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-07-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $253 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-07-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-07-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-07-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-06-03 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-05-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $2,688 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-05-02 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-05-02 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-05-02 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
| 2019-02-25 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGY ASSOCIATES OF MID OHIO | $788 | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Marion, OH, county Marion County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Marion, OH | County Marion County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 35,669 | 65,020 | 11,810,293 |
| Population, 2020 census P1 | 35,999 | 65,359 | 11,799,448 |
| Median age B01002 | 39.0 | 40.1 | 39.7 |
| Under 18 B01001 | 19.6% | 21.3% | 22.0% |
| 65 and over B01001 | 14.9% | 18.7% | 18.3% |
| Households B11001 | 12,445 | 24,683 | 4,863,191 |
| Foreign born B05002 | 1.6% | 1.5% | 5.2% |
| Median household income B19013 | $47,951 | $59,371 | $71,389 |
| Median family income B19113 | $60,903 | $76,382 | $92,749 |
| Per capita income B19301 | $22,852 | $30,260 | $40,552 |
| Poverty rate B17001 | 22.4% | 16.6% | 13.3% |
| Unemployment rate B23025 | 9.4% | 6.3% | 4.8% |
| Civilian labor force B23025 | 14,522 | 28,086 | 5,994,779 |
| Mean commute (minutes) B08013 | 21.0 | 24.5 | 23.4 |
| Bachelor's degree or higher B15003 | 10.5% | 14.7% | 31.5% |
| Housing units B25001 | 14,304 | 27,358 | 5,292,391 |
| Owner-occupied B25003 | 57.2% | 67.5% | 67.2% |
| Renters B25003 | 42.8% | 32.5% | 32.8% |
| Median home value B25077 | $119,500 | $156,800 | $214,800 |
| Median gross rent B25064 | $856 | $864 | $1,034 |
| White, not Hispanic B03002 | 79.5% | 86.3% | 75.8% |
| Black B03002 | 8.5% | 4.7% | 12.0% |
| Hispanic or Latino B03002 | 4.0% | 3.2% | 4.8% |
| Asian B03002 | 0.5% | 0.6% | 2.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Marion, OH.
Comments